Neuphoria Therapeutics (NEUP) Income Statement (2023 - 2026)
Income Statement report data from Sep 30, 2023 to Mar 31, 2026 for Neuphoria Therapeutics (NEUP).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||
Total Revenue | - | - | - | - | 15M (+2172.73%) | 660K | - | - | - | - | - |
Operating Expenses | |||||||||||
Research And Development | - | 700K (-81.53%) | 3.79M | - | 1.62M (-6.90%) | 1.74M (-8.42%) | 1.90M (-38.71%) | 3.10M (+158.33%) | 1.20M (-40.89%) | 2.03M (-34.30%) | 3.09M |
Selling General And Administrative | 1.69M (-20.66%) | 2.13M (+13.90%) | 1.87M | - | 1.41M (-46.39%) | 2.63M (+57.49%) | 1.67M (-29.83%) | 2.38M (+98.33%) | 1.20M (-52.38%) | 2.52M (+5.88%) | 2.38M |
Operating Expenses | 1.21M (-70.20%) | 4.06M (-28.14%) | 5.65M | - | 3.02M (-30.89%) | 4.37M (+22.41%) | 3.57M (-34.85%) | 5.48M (+129.29%) | 2.39M (-47.47%) | 4.55M (-16.82%) | 5.47M |
Depreciation And Amortization | - | - | 170K | - | - | - | 170K (-66.00%) | 500K | - | - | 170K |
Operating Income | |||||||||||
Operating Income | -1.21M (-70.20%) | -4.06M (-28.14%) | -5.65M | - | 12M | -3.70M (+3.64%) | -3.57M (-34.85%) | -5.48M (+129.29%) | -2.39M (-47.47%) | -4.55M (-16.82%) | -5.47M |
Ebit | -1.21M (-70.20%) | -4.06M (-28.14%) | -5.65M (+1312.50%) | -400.00K | 12M | -3.70M (+3.64%) | -3.57M (-34.85%) | -5.48M (+129.29%) | -2.39M (-47.47%) | -4.55M (-16.82%) | -5.47M |
EBITDA | -540.00K | 1.83M | -5.49M (+1272.50%) | -400.00K | 11M | -1.93M (-43.24%) | -3.40M (-25.76%) | -4.58M (+65.94%) | -2.76M (-39.87%) | -4.59M (-13.40%) | -5.30M |
Other Income / Expenses | |||||||||||
Interest Income | 190K (+11.76%) | 170K (+21.43%) | 140K | - | 10K (-66.67%) | 30K (-25.00%) | 40K (+33.33%) | 30K (-40.00%) | 50K (0.00%) | 50K (-44.44%) | 90K |
Net Interest Income | 190K (+11.76%) | 170K (+21.43%) | 140K | - | 10K (-66.67%) | 30K (-25.00%) | 40K (+33.33%) | 30K (-40.00%) | 50K (0.00%) | 50K (-44.44%) | 90K |
Other Non Operating Income | 670K (-88.62%) | 5.89M | -4.29M | - | -800.00K | 1.77M (-32.70%) | 2.63M (+13.85%) | 2.31M | -370.00K (+825.00%) | -40.00K (0.00%) | -40.00K |
Net Income | |||||||||||
Income Before Tax | -540.00K | 1.83M | -9.94M | - | 11M | -1.93M (+105.32%) | -940.00K (-65.44%) | -2.72M (-1.45%) | -2.76M (-39.87%) | -4.59M (-16.70%) | -5.51M |
Income Tax Expense | -30.00K (0.00%) | -30.00K (0.00%) | -30.00K | - | -80.00K | 10K | -130.00K (+333.33%) | -30.00K | 20K | -30.00K (0.00%) | -30.00K |
Net Income From Continuing Operations | -510.00K | 1.86M | -9.91M (+2377.50%) | -400.00K | 11M | -1.94M (+142.50%) | -800.00K (-70.26%) | -2.69M (-3.24%) | -2.78M (-38.90%) | -4.55M (-16.82%) | -5.47M |
Net Income | -510.00K | 1.86M | -9.91M (+2377.50%) | -400.00K | 11M | -1.94M (+142.50%) | -800.00K (-70.26%) | -2.69M (-3.24%) | -2.78M (-38.90%) | -4.55M (-16.82%) | -5.47M |
Comprehensive Income Net Of Tax | -350.00K | 2.43M | -9.86M | - | 11M | -3.23M (+1368.18%) | -220.00K (-98.58%) | -15.45M (+362.57%) | -3.34M (-18.54%) | -4.10M (-25.99%) | -5.54M |